Ligand Pharmaceuticals Inc (LGND)
114.58
+0.64
(+0.56%)
USD |
NASDAQ |
Dec 20, 16:00
115.00
+0.42
(+0.37%)
After-Hours: 20:00
Ligand Pharmaceuticals Enterprise Value: 1.945B for Dec. 20, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cellectar Biosciences Inc | -10.95M |
| Revance Therapeutics Inc | 570.21M |
| Pieris Pharmaceuticals Inc | -- |
| Zymeworks Inc | 676.73M |
| CNS Pharmaceuticals Inc | -0.5609M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.172M |
| Revenue (Quarterly) | 51.81M |
| Total Expenses (Quarterly) | 40.86M |
| EPS Diluted (Quarterly) | -0.39 |
| Gross Profit Margin (Quarterly) | 95.27% |
| Profit Margin (Quarterly) | -13.84% |
| Earnings Yield | 2.19% |
| Operating Earnings Yield | 0.87% |
| Normalized Earnings Yield | -0.7319 |